Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Detection of Atrial Fibrillation Using PPG From Smartphone Cameras (FLASH AF)

19 de agosto de 2026 atualizado por: Happitech BV

Detection of Atrial Fibrillation Using Photoplethysmography From Smartphone Cameras

The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Algorithm output will be compared to a gold standard of 12-lead ECG recorded with a simultaneous PPG measurement.

Visão geral do estudo

Descrição detalhada

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is increasing and is expected to continue increasing for decades,. Detection of AF episodes may be useful for the identification of undiagnosed AF and in making clinical management decisions that include oral anticoagulation, restoration and maintenance of sinus rhythm, control of ventricular rate, and risk factor modification. Treatment of AF is associated with improvements of quality of life, stroke prevention, and reduced risk of heart failure.

Traditionally, diagnosis of AF is done using an electrocardiogram, with low amplitude or absent p-waves and narrow complex "irregularly irregular" pattern intervals seen on the ECG,. After diagnosis, there are a variety of methods that can be used to manage AF. Ambulatory ECG monitoring, implantable monitoring devices, and over-the-counter wrist-worn devices have been used to manage patients with AF,,. However, these devices are inconvenient and expensive which limits their wide adoption into clinical practice. There is an unmet clinical need for an easy to use and inexpensive over-the-counter FDA-cleared products that can detect episodes of AF in real-time and notify patients to seek out further care when AF is suspected.

Recent technological advancements have allowed for the identification of AF using smartwatches, with device manufacturers gaining over-the-counter regulatory clearance for their irregular heart rate detection algorithms,. These wrist-worn devices use a light-based measurement method called photoplethysmography (PPG) to measure changes in light absorbance and reflectance to understand changes in blood flow in superficial vasculature. The waveform generated from this measurement can be used to measure parameters like pulse rate, respiratory rate, pulse rate variability and others in addition to detecting AF. The increasing ubiquity of smartphones worldwide has led to greater availability of heart rhythm diagnostics using smartphone photoplethysmography (PPG). Smartphone camera PPG technology uses the light-emitting diode in cameras to measure pulsatile changes in light intensity that are reflected from a finger and can be used to detect AF. The widespread availability of this technology has the potential to improve the accessibility and convenience of heart rhythm monitoring, particularly in remote or underserved areas. This could result in improvements in early detection and management of AF, leading to better patient outcomes. Several smartphone PPG-based algorithms have been developed that utilize smartphones' built-in cameras to detect AF. The sensitivity and specificity of these algorithms for the detection of AF range between 81%-100% and 85%-100% respectively. However, there is a lack of evidence regarding the performance of these algorithms in detecting AF in an out-of-hospital setting using a gold-standard reference.

Happitech has developed a proprietary software development kit (SDK) that can be utilized to measure patients' cardiovascular parameters and identify potential pathologies including AF. Happitech's algorithm requires users to place a digit directly against their phone camera, and the camera and underlying algorithm detect subtle differences in blood flow to calculate physiological parameters for monitoring and clinical use.

The purpose of this study is to validate the performance of Happitech's PPG-based algorithm for the detection of AF against a 12-lead ECG in a diverse population of patients including cardiology patients being evaluated as inpatients or at a cardiology clinic visit.

Tipo de estudo

Observacional

Inscrição (Estimado)

554

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Yosef Safi Harb, CEO
  • Número de telefone: +31 (0) 681885565
  • E-mail: yosef@happitech.com

Estude backup de contato

Locais de estudo

    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • Recrutamento
        • Nair Research, LLC dba Arrhythmia Research Group LLC
        • Contato:
        • Investigador principal:
          • Devi Nair, Doctor
    • Colorado
      • Littleton, Colorado, Estados Unidos, 80210
        • Recrutamento
        • South Denver Cardiology
        • Contato:
        • Investigador principal:
          • Srikanth Sundaram, Doctor
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Ainda não está recrutando
        • Tulane University
        • Contato:
          • Kunal Sameer, Associate Director of Ops
          • Número de telefone: 203-285-5666
          • E-mail: ksameer@tulane.edu
        • Investigador principal:
          • Nassair Marrouchi, Doctor
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73134
        • Recrutamento
        • CardioVascular Health Clinic
        • Contato:
        • Investigador principal:
          • Monica Lo, Doctor
    • Overijssel
      • Zwolle, Overijssel, Holanda, 8025 AB
        • Recrutamento
        • Isala Zwolle
        • Contato:
        • Investigador principal:
          • Sebastien Krul, Doctor

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Male and female patients aged 22 years or older who are cardiology patients consulting the cardiac outpatient clinic, 50% of whom have a rhythm of atrial fibrillation at the time of enrollment, and own a smartphone.

Descrição

Inclusion Criteria:

  1. Adults aged 22 years or older
  2. Owns a smartphone and knows how to operate and navigate different applications.
  3. Individuals able to read, understand, and sign the consent form.
  4. Cardiology patients consulting the cardiac outpatient clinic.
  5. History of persistent AF or other cardiac rhythm

Exclusion Criteria:

  1. Participants with cognitive impairments
  2. Individuals who cannot read, speak, and/or understand English
  3. Patients with implantable neurostimulators, cardiac implantable device in an atrial or ventricular paced rhythm documented on a 12-lead ECG during the initial study visit

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Sinus Rhythm
Patient visiting the Cardiology Clinic in Sinus Rhythm
12 Lead ECG is compared to a smartphone based PPG
Atrial Fibrillation
Patient visiting the Cardiology Clinic in Atrial Fibrillation
12 Lead ECG is compared to a smartphone based PPG
Other
Patient visiting the Cardiology Clinic with neither Sinus Rhythm or Atrial Fibrillation
12 Lead ECG is compared to a smartphone based PPG

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
To evaluate the sensitivity and specificity of the Heart Rhythm Software
Prazo: Through study completion, an average of 6 months

To evaluate the sensitivity and specificity of the Heart Rhythm Software algorithm running on a commercially available smartphone to detect atrial fibrillation segments using photoplethysmography (PPG) as measured through the phone's camera.

Se is defined as the percentage of patients with 90 second interval recordings scored by the Heart Rhythm Software algorithm as AF, out of all intervals determined by the Clinical Adjudication Committee (CAC) to be AF (gold standard).

Sp is defined as the percentage of patients with 90 second intervals scored by the Heart Rhythm Software algorithm as NSR out of all ECG recordings determined by the CAC to be NSR.

Through study completion, an average of 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Sensitivity & Specificity across subgroups
Prazo: through study completion, an average of 6 months
The accuracy of the Happitech Heart Rhythm Software algorithm in detecting irregular rhythm suspected of AF and regular rhythm suspected normal sinus rhythm will be further investigated in subgroups defined by ethnicity, race, BMI, age group, smartphone type, and Fitzpatrick scale score. The sensitivity and specificity will be presented as an estimate and associated 95% CI's, as well as a Chi-square or Fisher's Exact p-value to assess if all levels of the subgroup are homogeneous.
through study completion, an average of 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de junho de 2026

Conclusão Primária (Estimado)

1 de novembro de 2026

Conclusão do estudo (Estimado)

1 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

11 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de agosto de 2026

Primeira postagem (Real)

21 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever